Fantastic news from Solid Bio
30 Nov 2017
Solid Biosciences Initiates Clinical Trial for Gene Transfer Candidate SGT-001 in Patients with Duchenne Muscular Dystrophy
Solid Biosciences is a life science company focused on solving Duchenne muscular dystrophy.
Cambridge, MA, November 30, 2017 , Solid Biosciences.
Solid Biosciences announced today that it has initiated clinical trial activities for SGT-001, the company's lead microdystrophin gene transfer candidate for the treatment of Duchenne muscular dystrophy (DMD). The Phase I/II adaptive study, called IGNITE DMD, will evaluate the safety and efficacy of a single intravenous (IV) dose of SGT-001 in ambulatory and non-ambulatory adolescents and children with DMD. Enrollment will begin at the first clinical trial site in the United States in the coming days.
Read more about this exciting development in this article from Solid Biosciences or at the link below.
COPYRIGHT HARRISON’S FUND
ALL RIGHTS RESERVED | REGISTERED UK CHARITY NO. 1146662
SITE BY MZURI DESIGN